ArticleFrontiers in neurology2025
Efficacy of the herbal medicine Chotosan following treatment with Western medications for migraine accompanied by tension-type headache.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chotosan is herbal medicine that is effective for tension-type headache (TTH). This study aimed to evaluate the efficacy of Chotosan following treatment with Western medications for migraine accompanied by TTH. Methods: This was a single-center, single-arm, and retrospective observational study. Chotosan was prescribed in the following situations: responded to Western medications but effects weakened; could not continue taking Western medications due to side effects; responded to Western medications but still had frequent headaches; and refused to take antidepressants. The primary endpoint was to determine whether monthly headache days (MHDs) were decreased 1 month after starting Chotosan treatment. The efficacy of Chotosan was defined as meeting two criteria: MHDs decreased by 33% or more, and the patient was willing to take and actually continued taking the medication. The efficacy rate of Chotosan, changes in monthly migraine days, changes in monthly triptan and nontriptan tablet usage, and incidence of side effects were also evaluated. Results: Of 1,030 migraine patients, 51 patients were included in the analysis. Chotosan significantly reduced MHDs from a median of 19.0 [14.8-25.8] days to 14.0 [7.8-23.8] days, with an efficacy rate of 52.9%. Median monthly migraine days also decreased significantly from 3.0 [0.0-6.0] days to 1.0 [0.0-3.8] days. The median amounts of triptan and non-triptan tables decreased significantly from 6.0 [2.0-9.8] tablets to 4.0 [1.0-7.0] tablets, and median 10.0 [0.8-17.3] tablets to 5.0 [0.8-18.5] tablets, respectively. The incidence of side effects was 3.9%. Conclusion: For patients with migraine accompanied by TTH who have not responded adequately to Western medications, Chotosan is a treatment option worth considering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.